Business Description
AlzeCure Pharma AB
ISIN : SE0010133785
Total Employee Number:
10Compare
Compare
Traded in other countries / regions
ALZCUR.SwedenAC6.Germany IPO Date
2019-02-21Description
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.38 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.2 | |||||
3-Year EPS without NRI Growth Rate | 22.1 | |||||
3-Year FCF Growth Rate | 41.9 | |||||
3-Year Book Growth Rate | -33.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -17.39 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.32 | |||||
9-Day RSI | 54.28 | |||||
14-Day RSI | 58.21 | |||||
3-1 Month Momentum % | 455.56 | |||||
6-1 Month Momentum % | 282.67 | |||||
12-1 Month Momentum % | 76.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.36 | |||||
Quick Ratio | 1.36 | |||||
Cash Ratio | 1.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.6 | |||||
Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -252.5 | |||||
ROA % | -142.61 | |||||
ROIC % | -399.2 | |||||
3-Year ROIIC % | -35.63 | |||||
ROC (Joel Greenblatt) % | -2358.99 | |||||
ROCE % | -236.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 71.63 | |||||
Price-to-Tangible-Book | 53.4 | |||||
EV-to-EBIT | -13.18 | |||||
EV-to-EBITDA | -13.4 | |||||
EV-to-Forward-EBITDA | -2.64 | |||||
EV-to-FCF | -18.73 | |||||
| Price-to-Net-Current-Asset-Value | 53.4 | |||||
Earnings Yield (Greenblatt) % | -7.59 | |||||
FCF Yield % | -5.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AlzeCure Pharma AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.042 | ||
| Beta | 0.6748 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 1.58 | ||
| Volatility % | 311.34 | ||
| 14-Day RSI | 58.21 | ||
| 14-Day ATR (€) | 0.072445 | ||
| 20-Day SMA (€) | 0.4468 | ||
| 12-1 Month Momentum % | 76.08 | ||
| 52-Week Range (€) | 0.072291 - 0.736 | ||
| Shares Outstanding (Mil) | 131.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AlzeCure Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AlzeCure Pharma AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-11 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 44 days | ||
| General meeting for 2026 | 2026-06-29 16:00 | 0.38 (+19.63%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 0.08 (+0.00%) | ||
| Annual report for 2025 | 2026-04-08 | 0.11 (+9.52%) | ||
| AlzeCure Pharma presents at Stora Aktiedagarna | 2026-03-11 08:50 | 0.12 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.13 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-11 | 0.12 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-26 | 0.27 (+0.00%) | ||
| General meeting for 2025 | 2025-05-14 16:00 | 0.18 (+0.97%) |
Show
Entries
AlzeCure Pharma AB Frequently Asked Questions
What is AlzeCure Pharma AB(FRA:AC6)'s stock price today?
The current price of FRA:AC6 is €0.53. The 52 week high of FRA:AC6 is €0.74 and 52 week low is €0.07.
When is next earnings date of AlzeCure Pharma AB(FRA:AC6)?
The next earnings date of AlzeCure Pharma AB(FRA:AC6) is 2026-08-26.
Does AlzeCure Pharma AB(FRA:AC6) pay dividends? If so, how much?
AlzeCure Pharma AB(FRA:AC6) does not pay dividend.
Press Release
Articles on AlzeCure Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers